Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

BridgeBio Oncology Therapeutics, Inc. (BBOT)

As of 2026-11-21 · 12/15 boxes filled from SEC filings and market data

Report price $1.81 (close 2026-11-20)

Conclusion: WATCH

Conviction low · base case none · downside -40% · upside +50%

The market is not missing the burn: $145.3M of market cap sits under $315.3M of cash and investments at 2026-09-30, enterprise value is minus $170.1M and flagged as not real because the share count may be understated, and the stock pays 0.50x book on $293.4M of equity while TTM free cash flow is -$151.0M. No comparable peer multiple sets a base case — the peer table is mostly n/m and the one accepted name a weak match — so the call rests on the downside and upside alone. There is no base case: no independent multiple was available, and a base at today's multiple is today's price by construction. The label is WATCH, at low conviction, because the balance sheet is real but being consumed and the pipeline is binary. The downside case is -40.5% to $1.08, taken as -30.0% book value at a compressed P/B of 0.42x (today 0.5x). The upside case is +50.0% to $2.71, a re-rating to 0.75x on the cited dated catalyst, protected by the patent estate but not enough to underwrite a base value today.

Key numbers

  • Share price: $1.81
  • Market cap: $145.3M
  • Latest financial period: TTM to Sep 30, 2026
  • FCF yield: -104.0%
  • Price / book: 0.50x

The 15 boxes

  1. ✓ 1. Long-form business notes

    BBOT is a clinical-stage oncology company whose value rests on three Phase 1 oral small molecule programs, not product sales; the FY2024 filing under the former Helix Acquisition Corp. II name was a SPAC with no operations or revenue, while the FY2025 filing describes the merged clinical-stage company. Latest DATA show widening operating losses and cash burn: FY2025 operating loss $145.8M and operating cash flow -$113.9M; TTM to Sep 2026 operating loss $187.3M and operating cash flow -$150.9M, with cash $76.5M and short-term investments $117.4M. No product revenue, unit economics or segment detail are given in these sources.

  2. ✓ 2. Competitive advantage

    BBOT has no approved product and has never generated revenue, so there is no margin or return history to test a moat against — only a widening string of operating losses and cash burn. The claimed advantage is mechanistic: dual ON/OFF KRAS inhibition and a RAS-selective PI3Kα breaker, backed so far by preclinical head-to-head potency figures and company-described Phase 1 data, not by commercial results. Its competitors include AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer/Merck KGaA, Regeneron/Sanofi and Roche plus a long list of named KRAS and PI3Kα programs, and the 10-K itself concedes those rivals have far greater financial and development resources.

  3. ✓ 3. 10-Q takeaways

    The Q3 2026 10-Q shows a pre-revenue clinical-stage company spending less in the quarter but more year-to-date: three-month operating expenses fell 24% to $37.5 million (R&D $29.6 million, G&A $7.9 million) and the net loss narrowed to $34.2 million from $44.8 million, while nine-month R&D rose 43% to $118.6 million and the nine-month net loss widened to $132.7 million from $95.2 million. Cash, cash equivalents and marketable securities were $315.3 million at September 30, 2026, down $110.1 million from $425.5 million at December 31, 2025, after $108.6 million of nine-month operating cash burn; the earnings release says that funds operations into 2029, while the 10-Q only commits to at least twelve months from issuance. Management added financing capacity (a $500 million shelf declared effective September 10, 2026 and a $200 million ATM under which no shares had been sold as of September 30, 2026), and the quarter's news flow was clinical, not commercial.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans